###begin article-title 0
Hereditary diffuse gastric cancer: association with lobular breast cancer
###end article-title 0
###begin p 1
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 968 972 968 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
Hereditary diffuse gastric cancer (HDGC) has been shown to be caused by germline mutations in the gene CDH1 located at 16q22.1, which encodes the cell-cell adhesion molecule, E-cadherin. Not only does loss of expression of E-cadherin account for the morphologic differences between intestinal and diffuse gastric cancer (DGC) variants, but it also appears to lead to distinct cellular features which appear to be common amongst related cancers that have been seen in the syndrome. As in most hereditary cancer syndromes, multiple organ sites may be commonly affected by cancer, in HDGC, lobular carcinoma of the breast (LBC) and possibly other organ sites have been shown to be associated with the familial cancer syndrome. Given the complexity of HDGC, not only with regard to the management of the DGC risk, but also with regard to the risk for other related cancers, such as LBC, a multi-disciplinary approach is needed for the management of individuals with known CDH1 mutations.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 76 77 76 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 623 627 623 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 756 760 756 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 837 838 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 881 885 881 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1106 1110 1106 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1004 1012 <span type="species:ncbi:9606">patients</span>
Despite an overall decrease in the global incidence of gastric cancer (GC) [1], the incidence of the subtype, diffuse gastric cancer (DGC) has remained stable and may even be increasing [2]. Within the past ten years, germline mutations in CDH1, which encodes E-cadherin, have been found [3] in over 50% of hereditary diffuse gastric cancer (HDGC) families with at least two cases of GC, with one diagnosed as DGC before the age of 50 years [4]. Within these HDGC families, we and others have noted an overrepresentation of lobular breast cancer (LBC) [4-8]. This observation has led to efforts to determine whether or not CDH1 is a breast cancer susceptibility gene, distinct from its gastric cancer risk. Recently our group has reported a novel germline CDH1 truncating mutation (517insA) in an LBC family with no known history of GC [9]. Within this review we report a germline CDH1 mutation in a second family in which breast cancer is the predominant cancer diagnosis. The management of HDGC in all patients with a particular focus on the management of the breast cancer risk associated with germline CDH1 mutations will be discussed.
###end p 4
###begin title 5
Methods
###end title 5
###begin p 6
###xml 427 431 427 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
The described family was referred to the ongoing HDGC study at the British Columbia Cancer Agency from a cancer genetics clinic in Seattle, WA, USA. Informed consent was obtained from the proband by the referring genetic counselor following ascertainment of a detailed cancer family history and appropriate genetic counseling prior to germline mutation testing. Our laboratory carried out the molecular genetic testing for the CDH1 mutation on a research basis. Approval for the HDGC study is by the clinical research ethics board of the University of British Columbia.
###end p 6
###begin p 7
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 368 373 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 375 380 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 476 482 476 482 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 483 484 483 484 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 556 557 556 557 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 482 611 482 609 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="8">(<bold>a</bold>) Pedigree of family reported showing a predominance of breast cancer. (<bold>b</bold>) Sequence from family carrying 1565&#160;+&#160;1G&#8594;A mutation</p>
###xml 482 611 482 609 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="8">(<bold>a</bold>) Pedigree of family reported showing a predominance of breast cancer. (<bold>b</bold>) Sequence from family carrying 1565&#160;+&#160;1G&#8594;A mutation</p></caption>
###xml 611 611 609 609 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10689_2007_9172_Fig1_HTML" id="MO1"/>
###xml 476 611 476 609 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="8">(<bold>a</bold>) Pedigree of family reported showing a predominance of breast cancer. (<bold>b</bold>) Sequence from family carrying 1565&#160;+&#160;1G&#8594;A mutation</p></caption><graphic position="anchor" xlink:href="10689_2007_9172_Fig1_HTML" id="MO1"/></fig>
The proband (IV-4) was diagnosed with widely metastatic lobular breast cancer at age 53 years (Fig. 1a). Her family, of European ancestry, had a history of breast cancer diagnoses occurring in an autosomal dominant fashion on the maternal side of the family where her mother, aunt, and first cousin developed breast cancer in their 50's. Due to her high-risk pedigree BRCA1, BRCA2, and PTEN genetic testing was undertaken and all were negative. CDH1 testing was also pursued. Fig. 1(a) Pedigree of family reported showing a predominance of breast cancer. (b) Sequence from family carrying 1565 + 1G-->A mutation
###end p 7
###begin p 8
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 74 75 74 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
(a) Pedigree of family reported showing a predominance of breast cancer. (b) Sequence from family carrying 1565 + 1G-->A mutation
###end p 8
###begin title 9
Results
###end title 9
###begin p 10
###xml 48 49 48 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
All 16 exons were amplified for DHPLC analysis [6]. For exon 10 of CDH1, the initial amplicon failed and was therefore analyzed by direct sequencing and thus revealed a donor splice site mutation, 1565 + 1G > A (Fig. 1b). Due to its position at a donor splice site, this mutation is regarded as pathogenic [10].
###end p 10
###begin p 11
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
The proband's sisters (IV-2 and IV-6) participated in all aspects of the proband's genetic consultation. They were appropriately concerned about their risk of breast cancer, but had not thought much about the possibility of getting gastric cancer until the CDH1 mutation was found. IV-2 and IV-6 had predictive genetic testing for the CDH1 mutation testing and both were found to be negative. Other family members are being informed about the availability of predictive genetic testing.
###end p 11
###begin title 12
Discussion
###end title 12
###begin title 13
E-cadherin
###end title 13
###begin p 14
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 851 853 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1082 1084 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1086 1088 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1256 1258 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1340 1342 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1536 1538 1522 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1753 1755 1736 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1903 1905 1886 1888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 2194 2198 2177 2181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 2218 2220 2201 2203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 2314 2316 2297 2299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
CDH1 (OMIM *192090), located on chromosome 16q22.1 encodes, E-cadherin, an epithelial transmembrane cell-cell adhesion molecule and member of the cadherin superfamily of glycoproteins. In a zipper-like fashion, its extracellular domain forms calcium-dependent homodimers between the E-cadherin molecules of adjacent epithelial cells, to act as the primary mediator of epithelial cell adhesion at the adherens junction complex [11]. Through interactions of its cytoplasmic tail with multiple signalling and structural molecules, such as the catenins, E-cadherin, maintains cellular adhesion and epithelial architecture with this link to the cytoskeleton. The cytoplasmic tail of E-cadherin directly associates with beta-catenin and gamma-catenin which in turn binds to the f-actin microfilaments of the cytoskeleton, directly or through alpha-catenin [12]. p120-catenin also associates with E-cadherin's cytoplasmic tail at a different site, the juxtamembrane domain, and acts to both strengthen the adhesion between cells and regulate cadherin membrane trafficking and degradation [13, 14]. E-cadherin is considered to have an invasion suppressor role, where decreased expression permits cells to dissociate from each other in order to migrate and invade [15]. In cancers, this manifests as increased infiltrative and metastatic potential [16]. E-cadherin is also thought to act as a tumour suppressor, potentially through its interaction with the multipurpose beta -catenin molecule which is an effector of the WNT signalling pathway [17]. Loss of E-cadherin can result in beta-catenin release from the membrane and translocation to the nucleus where it complexes with Tcf/Lef-1 transcription factors to initiate transcription of WNT responsive genes [18]. Activation of these genes have been implicated in tumourigenesis through the WNT signalling pathway as seen in adenomatous polyposis coli (APC) [19]. In support of the role of E-cadherin as a tumour suppressor is the observation of abnormal or absent E-cadherin expression in precursor lesions of DGC and LBC, where the phenomenon is seen in in situ signet ring cell carcinomas found in prophylactic gastrectomy specimens from germline CDH1 mutation carriers [20] and the lobular carcinoma in situ lesions seen adjacent to invasive lobular breast cancers [21]. These examples suggest that loss of E-cadherin is an early or even tumour-initiating event, however the actual molecular basis of such a potential role of E-cadherin in such cases is unknown.
###end p 14
###begin p 15
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 451 452 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 492 496 492 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 508 512 508 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 765 767 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 928 934 928 934 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 957 961 957 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1004 1008 1004 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1075 1079 1075 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1168 1172 1168 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1219 1220 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1261 1262 1261 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1400 1404 1400 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 934 1451 934 1451 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="16">DGC and LBC associated <italic>CDH1</italic> germline mutations. Mutations shown above <italic>CDH1</italic> gene schematic occur in families with DGC history and those below <italic>CDH1</italic> occur in families with an additional or exclusive LBC history. In addition to the known <italic>CDH1</italic> germline mutations compiled by Kaurah et&#160;al. [<xref ref-type="bibr" rid="CR4">4</xref>], the recent mutation in an LBC family [<xref ref-type="bibr" rid="CR9">9</xref>] and novel mutation from this paper are shown and identified below the symbol denoting mutation type. * Denotes the halfway point of the <italic>CDH1</italic> coding sequence (1324 or the start of exon 10)</p>
###xml 934 1451 934 1451 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="16">DGC and LBC associated <italic>CDH1</italic> germline mutations. Mutations shown above <italic>CDH1</italic> gene schematic occur in families with DGC history and those below <italic>CDH1</italic> occur in families with an additional or exclusive LBC history. In addition to the known <italic>CDH1</italic> germline mutations compiled by Kaurah et&#160;al. [<xref ref-type="bibr" rid="CR4">4</xref>], the recent mutation in an LBC family [<xref ref-type="bibr" rid="CR9">9</xref>] and novel mutation from this paper are shown and identified below the symbol denoting mutation type. * Denotes the halfway point of the <italic>CDH1</italic> coding sequence (1324 or the start of exon 10)</p></caption>
###xml 1451 1451 1451 1451 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10689_2007_9172_Fig2_HTML" id="MO2"/>
###xml 928 1451 928 1451 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="16">DGC and LBC associated <italic>CDH1</italic> germline mutations. Mutations shown above <italic>CDH1</italic> gene schematic occur in families with DGC history and those below <italic>CDH1</italic> occur in families with an additional or exclusive LBC history. In addition to the known <italic>CDH1</italic> germline mutations compiled by Kaurah et&#160;al. [<xref ref-type="bibr" rid="CR4">4</xref>], the recent mutation in an LBC family [<xref ref-type="bibr" rid="CR9">9</xref>] and novel mutation from this paper are shown and identified below the symbol denoting mutation type. * Denotes the halfway point of the <italic>CDH1</italic> coding sequence (1324 or the start of exon 10)</p></caption><graphic position="anchor" xlink:href="10689_2007_9172_Fig2_HTML" id="MO2"/></fig>
Inactivating CDH1 mutations are found in 50% of sporadic DGCs [22, 23] and cluster between exons seven and nine [11], in contrast with the low percentage of mutations seen in sporadic intestinal type GCs [23]. Decreased expression of E-cadherin in DGCs may account for morphologic differences between intestinal and DGC variants [24]. Unlike somatic CDH1 mutations, germline mutations associated with DGC are distributed throughout the gene [7] (Fig. 2). In the cancers from individuals with CDH1 mutations, CDH1 acts as a classic tumour suppressor gene with loss of expression of the wildtype allele [25, 26]. In a single study of 6 hereditary DGC cancers, inactivation of the wild-type allele could be attributed to promoter hypermethylation in 5 (83%) of cases [26]. This finding warrants verification in a larger cohort as abnormal promoter methylation in early cancers could potentially form the basis of a screening test. Fig. 2DGC and LBC associated CDH1 germline mutations. Mutations shown above CDH1 gene schematic occur in families with DGC history and those below CDH1 occur in families with an additional or exclusive LBC history. In addition to the known CDH1 germline mutations compiled by Kaurah et al. [4], the recent mutation in an LBC family [9] and novel mutation from this paper are shown and identified below the symbol denoting mutation type. * Denotes the halfway point of the CDH1 coding sequence (1324 or the start of exon 10)
###end p 15
###begin p 16
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 466 470 466 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
DGC and LBC associated CDH1 germline mutations. Mutations shown above CDH1 gene schematic occur in families with DGC history and those below CDH1 occur in families with an additional or exclusive LBC history. In addition to the known CDH1 germline mutations compiled by Kaurah et al. [4], the recent mutation in an LBC family [9] and novel mutation from this paper are shown and identified below the symbol denoting mutation type. * Denotes the halfway point of the CDH1 coding sequence (1324 or the start of exon 10)
###end p 16
###begin title 17
Lobular breast cancer and diffuse gastric cancer: loss of E-cadherin
###end title 17
###begin p 18
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 332 336 332 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHK2</italic>
###xml 338 343 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRIP1</italic>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2</italic>
###xml 355 358 355 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 972 974 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
Currently germline mutations in single genes account for approximately 5-10% of breast cancer [27]. High penetrance genes such as BRCA1 and 2 account for 3-8%, and TP53 and PTEN as seen in Li-Fraumeni and Cowden syndrome together only account for <0.1% of breast cancer diagnoses [28]. Other medium and low penetrance genes such as CHK2, BRIP1, PALB2 and ATM [29-32] have been identified, however, there still remains a proportion of hereditary breast cancer not yet determined. LBC accounts for approximately 10% of all breast cancers compared to the other major histologic subtype, invasive ductal carcinoma (IDC) [33]. Several factors suggest that LBC has a stronger hereditary basis relative to IDC, such as the higher frequency of bilateral disease [33], and also where excess familiality of LBC has been observed in population studies [34]. LBCs compose only 3% and 9% of the breast cancer tumour types seen in germline BRCA 1 and 2 mutation carriers, respectively [35], illustrating that the genetic risk factors for the majority of cases are unaccounted for by these genes.
###end p 18
###begin p 19
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 458 462 458 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 553 557 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
The histology of LBC is characterized by infiltrative cancer cells which are isolated, highly dispersive and demonstrate a growth pattern with scattered and single files of tumor cells dispersed in stromal tissue [36]. This pathologic appearance is remarkably similar to DGCs and both LBC and DGC demonstrate characteristic mucinous, signet ring cells. This is not unexpected as E-cadherin staining is absent in 85% of sporadic invasive LBC [37] and somatic CDH1 mutations have been identified in 56% of sporadic LBCs [38]. Furthermore, in IDC, somatic CDH1 mutations are not found [38] and complete loss of E-cadherin expression is an uncommon feature. As loss of E-cadherin expression is a distinctive trait of both LBCs and DGCs, it likely contributes to the unique histopathologic features shared by the two cancers.
###end p 19
###begin p 20
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 632 636 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 745 749 745 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 928 929 928 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 957 958 957 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1109 1110 1109 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-</italic>
###xml 1121 1125 1121 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1473 1475 1473 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 1640 1642 1640 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
There are some differences with regard to the nature of the mutations seen in LBC and DGC. Generally mutations associated with sporadic LBC have been found to be nonsense or frameshift mutations [39] which encode truncated, non-functional proteins, whereas in sporadic DGC, mutations have generally been found to be splice site and in-frame mutations [11]. In sporadic LBC, mutations in CDH1 are spread throughout the gene [11] compared with the mutations seen in sporadic DGC which tend to cluster. Germline CDH1 mutations associated with DGC and/or LBC occur throughout the gene (Fig. 2). However, when the DGC and LBC associated CDH1 mutations are tabulated and compared based on their 3' or 5' positions relative to the halfway point of the CDH1 coding sequence (1324 or the start of exon 10), LBC associated mutations show a statistically significant trend towards clustering at the 3' end (Fisher's exact test, two-tailed P-value equals 0.0467) (Fig. 2). As this association is of weak statistical significance, it is unlikely to impact clinical testing strategies. Future analyses of novel germline LBC-associated CDH1 mutations should help to confirm this observation. Another difference between the molecular genetics of the two types of cancers, is that in sporadic LBC, silencing of E-cadherin expression is generally accomplished by a mutation in one allele in combination with loss of heterozygosity (LOH) or promoter hypermethylation in the remaining allele [40]. This is in contrast to sporadic DGC, where biallellic inactivation is achieved by mutations in one allele in concert with promoter hypermethylation in the other [41].
###end p 20
###begin p 21
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
We have recently identified a truncating germline CDH1 mutation in an LBC family where analysis of the tumour was suggestive of partial LOH in the WT allele [9]. Our current case demonstrates a germline CDH1 mutation (1565 + 1G > A) in a predominantly breast cancer family, which is predicted to disrupt splicing. The mutation is in the same conserved position as a previously reported mutation (1565 + 1G > T) which was found in an Arabian HDGC family with no recorded history of breast cancer [42]. Moreover, a previous study reported a germline missense mutation in a proband with LBC but did not detail family history, or functionally characterize the missense mutation [43]. These examples demonstrate the need for further studies of germline mutations in LBC families in order to determine the mutation frequency and potential genotype-phenotype correlations.
###end p 21
###begin title 22
Lobular breast cancer and HDGC
###end title 22
###begin p 23
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
Breast cancer has been observed in HDGC kindreds to the extent where clustering of LBCs within HDGC families has led to the misclassification of families as breast cancer kindreds who test negative for BRCA1/2 mutations [4]. In 1998, Keller described the first case of histologically defined LBC in association with HDGC [5]. Since then, several more HDGC families with associated breast cancer were reported where it was observed, that these cases were LBCs when pathology was available [4, 6-8].
###end p 23
###begin p 24
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 678 682 678 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
Prior to establishment of the association between HDGC and LBC, several efforts to determine whether CDH1 was a breast cancer susceptibility gene were attempted in view of the well-recognised phenotype of loss of E-cadherin expression displayed by the breast cancer subtype. For various reasons these studies failed to demonstrate the link. Rahman et al. examined 65 cases of lobular carcinoma in situ, however did not pre-screen the cases based on family history and included a wide age range, from 26 to 71 years, not necessarily in keeping with the usual age of onset seen in hereditary cancer syndromes [44]. Salashor examined 19 breast cancer tumours exhibiting LOH at the CDH1 locus, however of those, only 3 were confirmed to be pure LBC or mixed LBC/IDC pathology [45]. Lei examined 13 familial LBC cases and found no mutations, however did not define the extent of the family history [46].
###end p 24
###begin p 25
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 400 404 400 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 469 473 469 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 704 708 704 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 877 881 877 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 911 912 911 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
Penetrance data based on 11 HDGC families, estimated the cumulative risk for LBC for female mutation carriers to be 39% (95% CI, 12-84%) by 80 years of age [47]. More recently we have published an estimated cumulative risk for breast cancer for females by the age of 75 years as being 52% (95% CI, 29-94%) from analysis of 4 predominantly gastric cancer pedigrees from Newfoundland with the 2398delC CDH1 founder mutation [4]. This is with the caveat that LBC risk for CDH1 mutation carriers has been assessed within high risk HDGC families, leading to a potential ascertainment bias and underestimation of the role of CDH1 mutations in LBC development. To accommodate for this we have begun analysis of CDH1 mutations within familial lobular breast cancer families or those families ascertained through a relatively young index case with confirmed LBC and have found germline CDH1 mutations in these kindreds [9].
###end p 25
###begin title 26
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
Clinical implications of CDH1 associated LBC risk
###end title 26
###begin p 27
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 324 329 324 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 75 80 <span type="species:ncbi:9606">women</span>
###xml 112 117 <span type="species:ncbi:9606">women</span>
###xml 166 171 <span type="species:ncbi:9606">women</span>
###xml 200 205 <span type="species:ncbi:9606">women</span>
###xml 302 307 <span type="species:ncbi:9606">women</span>
###xml 442 447 <span type="species:ncbi:9606">women</span>
###xml 527 532 <span type="species:ncbi:9606">women</span>
At this time, it seems reasonable to conclude that at least four groups of women are at increased risk for LBC: women with LBC and a family history of breast cancer, women with a known CDH1 mutation, women from families with diffuse gastric cancer in whom no CDH1 mutation has yet been identified; and women with a germline BRCA2 mutation. Since there has not yet been a large population based study of the prevalence of CDH1 mutations among women with lobular breast cancer, it is premature to recommend genetic evaluation to women with a family history of breast cancer unless, at the very least, one of the breast cancers can be shown to have been lobular. Additional research can be expected to provide better guidance for these families.
###end p 27
###begin p 28
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 1129 1131 1129 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">50</xref>
###xml 100 105 <span type="species:ncbi:9606">women</span>
###xml 144 149 <span type="species:ncbi:9606">women</span>
###xml 237 242 <span type="species:ncbi:9606">women</span>
###xml 351 356 <span type="species:ncbi:9606">women</span>
###xml 781 786 <span type="species:ncbi:9606">women</span>
###xml 1091 1096 <span type="species:ncbi:9606">women</span>
Although there are not yet definitive data available on surveillance or risk reduction programs for women with known CDH1 mutations or untested women from CDH1-positive families, the high lifetime risk of LBC (39-52%) [4, 47] that these women face mandates their careful management. We suggest that they follow the recommendations for other high-risk women with hereditary breast cancer predisposition. This subgroup should be advised to practice breast self-examination; and to have annual mammograms, and semiannual clinical breast examination, beginning at least by age 30. There is certainly interest in regular bilateral breast MRI, as lobular breast cancer are known to frequently elude mammographic detection because they do not form masses or develop calcifications. These women can also be counseled to consider hormonal chemoprevention, since most LBCs are estrogen receptor positive [33], and both tamoxifen and raloxifene reduce the risk of estrogen receptor positive [48, 49] breast cancers in randomized trials. In addition, the risk reduction was greatest with both agents in women with lobular carcinoma in situ [50].
###end p 28
###begin p 29
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">51</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">52</xref>
###xml 79 84 <span type="species:ncbi:9606">women</span>
###xml 364 369 <span type="species:ncbi:9606">women</span>
Prophylactic mastectomy may also be considered an option by some CDH1-positive women, particularly those who have been previously diagnosed with breast cancer in one breast or those who have had to undergo multiple biopsies for abnormal clinical findings. Several studies have reported a 90% reduction in breast cancer incidence with prophylactic mastectomy among women with a strong family history or with a germline BRCA1 or BRCA2 mutation [51, 52]. The published series include some lobular breast cancers, but not at numbers sufficient to permit meaningful subset analysis at this time.
###end p 29
###begin title 30
Management of hereditary diffuse gastric cancer
###end title 30
###begin p 31
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 385 389 385 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">53</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 968 969 968 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">55</xref>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 1179 1180 1179 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1412 1414 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">57</xref>
###xml 168 171 <span type="species:ncbi:9606">men</span>
###xml 186 191 <span type="species:ncbi:9606">women</span>
Penetrance studies examining data from HDGC families, have estimated the lifetime risk of developing gastric cancer by age 75 and 80 respectively, to be from 40-67% in men, to 63-83% in women [4, 47]. Although identification of germline CDH1 mutations has enabled a significant proportion of HDGC families to utilise predictive testing to determine their individual risks of GC within CDH1 mutation positive pedigrees, unfortunately screening for DGC is ineffective and the current recommendation is for consideration of prophylactic gastrectomy in mutation positive individuals. Positron emission tomography [53] and chromoendoscopic-directed biopsies [54] have been proposed over basic endoscopy as more sensitive means of screening carriers, however screening methods have been consistently undermined by the recurrent discovery of multifocal DGC lesions underlying normal mucosa in prophylactic gastrectomy specimens of individuals with recent negative screening [4, 55, 56]. Regardless of the current limitations of screening, it is currently recommended that consideration for genetic testing and screening begin in at risk individuals in the late teens or early twenties [4] and that prophylactic total gastrectomy be considered in the early twenties for mutation carriers. Female mutation carriers will need specialized counseling to the potential nutritional effects on pregnancy following gastrectomy [57]. Further studies are currently underway to examine the quality of life impact of prophylactic gastrectomies. In the case report herein, although there was a GC in the maternal grandfather, the family history was more striking for the large number of breast cancer cases. This highlights the particular challenges we currently face with regard to counseling these families which appear to be mainly breast cancer, as it is unknown if the penetrance of DGC in this family is as high as it is in other HDGC pedigrees.
###end p 31
###begin title 32
Conclusion
###end title 32
###begin p 33
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 373 376 373 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">58</xref>
###xml 532 536 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 704 711 704 711 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 711 785 711 785 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">Other syndromes with familial susceptibility to breast and gastric cancers</p>
###xml 711 785 711 785 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">Other syndromes with familial susceptibility to breast and gastric cancers</p></caption>
###xml 785 793 785 793 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Syndrome</th>
###xml 793 812 793 812 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mode of inheritance</th>
###xml 812 830 812 830 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Associated gene(s)</th>
###xml 830 856 830 856 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sites of primary cancer(s)</th>
###xml 856 899 856 899 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Evidence for association with the syndrome </th>
###xml 785 899 785 899 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Syndrome</th><th align="left">Mode of inheritance</th><th align="left">Associated gene(s)</th><th align="left">Sites of primary cancer(s)</th><th align="left">Evidence for association with the syndrome </th></tr>
###xml 785 899 785 899 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Syndrome</th><th align="left">Mode of inheritance</th><th align="left">Associated gene(s)</th><th align="left">Sites of primary cancer(s)</th><th align="left">Evidence for association with the syndrome </th></tr></thead>
###xml 899 937 899 937 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BRCA2 Hereditary Breast/Ovarian Cancer</td>
###xml 937 939 937 939 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 939 944 939 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 939 944 939 944 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>BRCA2</italic></td>
###xml 950 950 950 950 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 955 955 955 955 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 961 961 961 961 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 944 969 944 969 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Breast<break/>Ovary<break/>Larynx<break/>Prostate</td>
###xml 1126 1128 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">59</xref>
###xml 1129 1129 1129 1129 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1189 1191 1189 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">60</xref>
###xml 1192 1192 1192 1192 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1250 1252 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR61">61</xref>
###xml 1253 1253 1253 1253 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1396 1398 1396 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">62</xref>
###xml 1400 1400 1400 1400 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1538 1543 1538 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 1545 1547 1545 1547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR63">63</xref>
###xml 969 1549 969 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 45% (95% confidence interval (CI) 31&#8211;56%) [<xref ref-type="bibr" rid="CR59">59</xref>]<break/>Familial aggregations of both BC and GC have been reported [<xref ref-type="bibr" rid="CR60">60</xref>]<break/>In a study of 173 families, relative risk for GC was 2.6 [<xref ref-type="bibr" rid="CR61">61</xref>]<break/>Among Ashkenazi Jewish GC patients, the frequency of 617delT mutation is five times that of the general Ashkenazi Jewish population frequency [<xref ref-type="bibr" rid="CR62">62</xref>] <break/>Among other cancers, GC occurred in first degree relatives when mutations were located in the ovarian cancer cluster region of exon 11 of <italic>BRCA2</italic> [<xref ref-type="bibr" rid="CR63">63</xref>] </td>
###xml 899 1549 899 1549 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BRCA2 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA2</italic></td><td align="left">Breast<break/>Ovary<break/>Larynx<break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 45% (95% confidence interval (CI) 31&#8211;56%) [<xref ref-type="bibr" rid="CR59">59</xref>]<break/>Familial aggregations of both BC and GC have been reported [<xref ref-type="bibr" rid="CR60">60</xref>]<break/>In a study of 173 families, relative risk for GC was 2.6 [<xref ref-type="bibr" rid="CR61">61</xref>]<break/>Among Ashkenazi Jewish GC patients, the frequency of 617delT mutation is five times that of the general Ashkenazi Jewish population frequency [<xref ref-type="bibr" rid="CR62">62</xref>] <break/>Among other cancers, GC occurred in first degree relatives when mutations were located in the ovarian cancer cluster region of exon 11 of <italic>BRCA2</italic> [<xref ref-type="bibr" rid="CR63">63</xref>] </td></tr>
###xml 1549 1587 1549 1587 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BRCA1 Hereditary Breast/Ovarian Cancer</td>
###xml 1587 1589 1587 1589 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 1589 1594 1589 1594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1589 1594 1589 1594 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>BRCA1</italic></td>
###xml 1600 1600 1600 1600 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1606 1606 1606 1606 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1594 1614 1594 1614 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Breast<break/>Ovary <break/>Prostate</td>
###xml 1783 1785 1783 1785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR64">64</xref>
###xml 1786 1786 1786 1786 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1828 1830 1828 1830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR64">64</xref>
###xml 1614 1831 1614 1831 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 72.8% (95% confidence interval [CI]&#160;=&#160;67.9% to 77.7%) [<xref ref-type="bibr" rid="CR64">64</xref>]<break/>There is a 4 times increased risk for GC [<xref ref-type="bibr" rid="CR64">64</xref>]</td>
###xml 1549 1831 1549 1831 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">BRCA1 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA1</italic></td><td align="left">Breast<break/>Ovary <break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 72.8% (95% confidence interval [CI]&#160;=&#160;67.9% to 77.7%) [<xref ref-type="bibr" rid="CR64">64</xref>]<break/>There is a 4 times increased risk for GC [<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr>
###xml 1831 1853 1831 1853 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Peutz-Jeghers Syndrome</td>
###xml 1853 1855 1853 1855 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 1855 1861 1855 1861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STK 11</italic>
###xml 1855 1861 1855 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>STK 11</italic></td>
###xml 1861 1888 1861 1888 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gastrointestinal (GI) tract</td>
###xml 2001 2003 2001 2003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">65</xref>
###xml 2005 2005 2005 2005 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2102 2104 2102 2104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">65</xref>
###xml 1888 2106 1888 2106 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GC is considered an integral tumor of the syndrome with a relative risk of 213 (95% confidence interval 96&#8211;368) [<xref ref-type="bibr" rid="CR65">65</xref>] <break/>BC is considered an integral tumor of the syndrome with a relative risk of 15.2 (95% CI 7.6&#8211;27) [<xref ref-type="bibr" rid="CR65">65</xref>] </td>
###xml 1831 2106 1831 2106 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Peutz-Jeghers Syndrome</td><td align="left">AD</td><td align="left"><italic>STK 11</italic></td><td align="left">Gastrointestinal (GI) tract</td><td align="left">GC is considered an integral tumor of the syndrome with a relative risk of 213 (95% confidence interval 96&#8211;368) [<xref ref-type="bibr" rid="CR65">65</xref>] <break/>BC is considered an integral tumor of the syndrome with a relative risk of 15.2 (95% CI 7.6&#8211;27) [<xref ref-type="bibr" rid="CR65">65</xref>] </td></tr>
###xml 2106 2121 2106 2121 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cowden Syndrome</td>
###xml 2121 2123 2121 2123 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 2123 2127 2123 2127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 2123 2127 2123 2127 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>PTEN</italic></td>
###xml 2133 2133 2133 2133 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2140 2140 2140 2140 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2127 2151 2127 2151 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Breast<break/>Thyroid<break/>Endometrium</td>
###xml 2231 2233 2231 2233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR66">66</xref>
###xml 2235 2237 2235 2237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR67">67</xref>
###xml 2238 2238 2238 2238 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2302 2304 2302 2304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR68">68</xref>
###xml 2151 2305 2151 2305 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC is considered an integral tumor of the syndrome with an incidence of 22&#8211;50% [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]<break/>GC in&#160;situ has been reported in a patient with Cowden Syndrome [<xref ref-type="bibr" rid="CR68">68</xref>]</td>
###xml 2106 2305 2106 2305 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Cowden Syndrome</td><td align="left">AD</td><td align="left"><italic>PTEN</italic></td><td align="left">Breast<break/>Thyroid<break/>Endometrium</td><td align="left">BC is considered an integral tumor of the syndrome with an incidence of 22&#8211;50% [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]<break/>GC in&#160;situ has been reported in a patient with Cowden Syndrome [<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr>
###xml 2305 2325 2305 2325 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Li-Fraumeni Syndrome</td>
###xml 2325 2327 2325 2327 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 2327 2331 2327 2331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 2331 2331 2331 2331 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2331 2335 2331 2335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHK2</italic>
###xml 2327 2335 2327 2335 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>TP53</italic><break/><italic>CHK2</italic></td>
###xml 2341 2341 2341 2341 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2355 2355 2355 2355 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2372 2372 2372 2372 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2378 2378 2378 2378 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2392 2392 2392 2392 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2401 2401 2401 2401 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2335 2418 2335 2418 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Breast<break/>Adrenal cortex<break/>Connective tissue<break/>Kidney<break/>Nervous system<break/>Pancreas <break/>White blood cells</td>
###xml 2495 2497 2495 2497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR69">69</xref>
###xml 2498 2498 2498 2498 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2555 2557 2555 2557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR70">70</xref>
###xml 2558 2558 2558 2558 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2567 2571 2567 2571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 2621 2625 2621 2625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 2637 2639 2637 2639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR71">71</xref>
###xml 2640 2642 2640 2642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR73">73</xref>
###xml 2643 2643 2643 2643 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2656 2660 2656 2660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHK2</italic>
###xml 2711 2713 2711 2713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 2784 2786 2784 2786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR74">74</xref>
###xml 2418 2787 2418 2787 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC is frequently found in families with this cancer susceptibility syndrome [<xref ref-type="bibr" rid="CR69">69</xref>]<break/>Chompret expanded the spectrum of cancers to include GC [<xref ref-type="bibr" rid="CR70">70</xref>]<break/>Germline <italic>TP53</italic> mutations have been found in GC families without <italic>CDH1</italic> mutations [<xref ref-type="bibr" rid="CR71">71</xref>&#8211;<xref ref-type="bibr" rid="CR73">73</xref>]<break/>The 1100delC <italic>CHK2</italic> allele confers a 2.2 fold risk of BC to carriers [<xref ref-type="bibr" rid="CR29">29</xref>], however germline mutations in GC kindreds have not been identified [<xref ref-type="bibr" rid="CR74">74</xref>]</td>
###xml 2305 2787 2305 2787 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Li-Fraumeni Syndrome</td><td align="left">AD</td><td align="left"><italic>TP53</italic><break/><italic>CHK2</italic></td><td align="left">Breast<break/>Adrenal cortex<break/>Connective tissue<break/>Kidney<break/>Nervous system<break/>Pancreas <break/>White blood cells</td><td align="left">BC is frequently found in families with this cancer susceptibility syndrome [<xref ref-type="bibr" rid="CR69">69</xref>]<break/>Chompret expanded the spectrum of cancers to include GC [<xref ref-type="bibr" rid="CR70">70</xref>]<break/>Germline <italic>TP53</italic> mutations have been found in GC families without <italic>CDH1</italic> mutations [<xref ref-type="bibr" rid="CR71">71</xref>&#8211;<xref ref-type="bibr" rid="CR73">73</xref>]<break/>The 1100delC <italic>CHK2</italic> allele confers a 2.2 fold risk of BC to carriers [<xref ref-type="bibr" rid="CR29">29</xref>], however germline mutations in GC kindreds have not been identified [<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr>
###xml 2787 2817 2787 2817 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Familial Adenomatous Polyposis</td>
###xml 2817 2819 2817 2819 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 2819 2822 2819 2822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 2819 2822 2819 2822 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>APC</italic></td>
###xml 2838 2838 2838 2838 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2846 2846 2846 2846 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2853 2853 2853 2853 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2822 2861 2822 2861 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colon and rectum<break/>Duodenum<break/>Thyroid<break/>Pancreas</td>
###xml 2941 2943 2941 2943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR76">76</xref>
###xml 2944 2944 2944 2944 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3007 3010 3007 3010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 3018 3020 3018 3020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR77">77</xref>
###xml 3022 3024 3022 3024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR78">78</xref>
###xml 3025 3025 3025 3025 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3068 3071 3068 3071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 3073 3075 3073 3075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 2861 3076 2861 3076 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Literature review by Shimoyama et&#160;al. totalled 30 reported cases of GC and FAP [<xref ref-type="bibr" rid="CR76">76</xref>]<break/>47% to 49% of primary BCs had promoter hypermethylation at the <italic>APC</italic> locus [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]<break/>23% of LBCs have been shown to have LOH of <italic>APC</italic> [<xref ref-type="bibr" rid="CR43">43</xref>]</td>
###xml 2787 3076 2787 3076 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Familial Adenomatous Polyposis</td><td align="left">AD</td><td align="left"><italic>APC</italic></td><td align="left">Colon and rectum<break/>Duodenum<break/>Thyroid<break/>Pancreas</td><td align="left">Literature review by Shimoyama et&#160;al. totalled 30 reported cases of GC and FAP [<xref ref-type="bibr" rid="CR76">76</xref>]<break/>47% to 49% of primary BCs had promoter hypermethylation at the <italic>APC</italic> locus [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]<break/>23% of LBCs have been shown to have LOH of <italic>APC</italic> [<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr>
###xml 3076 3137 3076 3137 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Lynch Syndrome (Hereditary Nonpolyposis Colon Cancer (HNPCC))</td>
###xml 3137 3139 3137 3139 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 3139 3144 3139 3144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH2</italic>
###xml 3144 3144 3144 3144 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3144 3149 3144 3149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1</italic>
###xml 3149 3149 3149 3149 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3149 3154 3149 3154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH6</italic>
###xml 3154 3154 3154 3154 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3154 3159 3154 3159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS1</italic>
###xml 3159 3159 3159 3159 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3159 3164 3159 3164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hPMS2</italic>
###xml 3139 3164 3139 3164 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>hMSH2</italic><break/><italic>hMLH1</italic><break/><italic>hMSH6</italic><break/><italic>hPMS1</italic><break/><italic>hPMS2</italic></td>
###xml 3180 3180 3180 3180 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3191 3191 3191 3191 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3199 3199 3199 3199 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3214 3214 3214 3214 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3224 3224 3224 3224 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3230 3230 3230 3230 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3235 3235 3235 3235 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3239 3239 3239 3239 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3247 3247 3247 3247 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3252 3252 3252 3252 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3270 3270 3270 3270 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3164 3283 3164 3283 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Colon and rectum<break/>Endometrium<break/>Stomach <break/>Small intestine<break/>Urothelium<break/>Kidney<break/>Ovary<break/>Skin<break/>Pancreas<break/>Brain<break/>White blood cells <break/>Biliary tract</td>
###xml 3348 3352 3348 3352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
###xml 3356 3360 3356 3360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MSH2</italic>
###xml 3372 3374 3372 3374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR76">76</xref>
###xml 3375 3375 3375 3375 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3375 3380 3375 3380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1</italic>
###xml 3473 3475 3473 3475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR79">79</xref>
###xml 3476 3476 3476 3476 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3523 3528 3523 3528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1</italic>
###xml 3548 3550 3548 3550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR80">80</xref>
###xml 3551 3551 3551 3551 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3560 3565 3560 3565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH2</italic>
###xml 3609 3614 3609 3614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH2</italic>
###xml 3635 3637 3635 3637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR81">81</xref>
###xml 3638 3638 3638 3638 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 3743 3745 3743 3745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR82">82</xref>
###xml 3283 3746 3283 3746 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gastric cancer accounted for 5% of cancers in families harboring <italic>MLH1</italic> or <italic>MSH2</italic> mutations [<xref ref-type="bibr" rid="CR76">76</xref>]<break/><italic>hMLH1</italic> mutations in large kindred segregated with BCs exhibiting microsatellite instability (MSI) [<xref ref-type="bibr" rid="CR79">79</xref>]<break/>A slight increased incidence of BC was seen in <italic>hMLH1</italic> mutation carriers [<xref ref-type="bibr" rid="CR80">80</xref>]<break/>Germline <italic>hMSH2</italic> mutation carrier with BC exhibited LOH for <italic>hMSH2</italic> in tumors analyzed [<xref ref-type="bibr" rid="CR81">81</xref>]<break/>Analysis of primary invasive BCs demonstrated that 25% of tumours were immunonegative for MSH2 staining [<xref ref-type="bibr" rid="CR82">82</xref>]</td>
###xml 3076 3746 3076 3746 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Lynch Syndrome (Hereditary Nonpolyposis Colon Cancer (HNPCC))</td><td align="left">AD</td><td align="left"><italic>hMSH2</italic><break/><italic>hMLH1</italic><break/><italic>hMSH6</italic><break/><italic>hPMS1</italic><break/><italic>hPMS2</italic></td><td align="left">Colon and rectum<break/>Endometrium<break/>Stomach <break/>Small intestine<break/>Urothelium<break/>Kidney<break/>Ovary<break/>Skin<break/>Pancreas<break/>Brain<break/>White blood cells <break/>Biliary tract</td><td align="left">Gastric cancer accounted for 5% of cancers in families harboring <italic>MLH1</italic> or <italic>MSH2</italic> mutations [<xref ref-type="bibr" rid="CR76">76</xref>]<break/><italic>hMLH1</italic> mutations in large kindred segregated with BCs exhibiting microsatellite instability (MSI) [<xref ref-type="bibr" rid="CR79">79</xref>]<break/>A slight increased incidence of BC was seen in <italic>hMLH1</italic> mutation carriers [<xref ref-type="bibr" rid="CR80">80</xref>]<break/>Germline <italic>hMSH2</italic> mutation carrier with BC exhibited LOH for <italic>hMSH2</italic> in tumors analyzed [<xref ref-type="bibr" rid="CR81">81</xref>]<break/>Analysis of primary invasive BCs demonstrated that 25% of tumours were immunonegative for MSH2 staining [<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr>
###xml 3746 3773 3746 3773 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Ataxia-telangiectasia (AT)</td>
###xml 3773 3775 3773 3775 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AR</td>
###xml 3775 3778 3775 3778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 3775 3778 3775 3778 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>ATM</italic></td>
###xml 3778 3795 3778 3795 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">White blood cells</td>
###xml 3895 3898 3895 3898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 4009 4011 3985 3987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 4012 4012 3988 3988 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4067 4069 4043 4045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR83">83</xref>
###xml 4070 4072 4046 4048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR85">85</xref>
###xml 4073 4073 4049 4049 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4166 4168 4142 4144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR86">86</xref>
###xml 3795 4169 3795 4145 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mutations causing AT in homozygotes, confer susceptibility to BC in heterozygotes, where women with <italic>ATM</italic> mutations have a &#8764;2-fold risk of BC and &#8764;15% of these women will develop the disease [<xref ref-type="bibr" rid="CR32">32</xref>]<break/>GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR83">83</xref>&#8211;<xref ref-type="bibr" rid="CR85">85</xref>]<break/>There is evidence of excess risks of GC in heterozygotes (RR&#160;=&#160;3.39, 95% CI&#160;=&#160;0.86 to 13.4) [<xref ref-type="bibr" rid="CR86">86</xref>]</td>
###xml 3746 4169 3746 4145 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Ataxia-telangiectasia (AT)</td><td align="left">AR</td><td align="left"><italic>ATM</italic></td><td align="left">White blood cells</td><td align="left">Mutations causing AT in homozygotes, confer susceptibility to BC in heterozygotes, where women with <italic>ATM</italic> mutations have a &#8764;2-fold risk of BC and &#8764;15% of these women will develop the disease [<xref ref-type="bibr" rid="CR32">32</xref>]<break/>GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR83">83</xref>&#8211;<xref ref-type="bibr" rid="CR85">85</xref>]<break/>There is evidence of excess risks of GC in heterozygotes (RR&#160;=&#160;3.39, 95% CI&#160;=&#160;0.86 to 13.4) [<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr>
###xml 4169 4190 4145 4166 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Xeroderma pigmentosum</td>
###xml 4190 4192 4166 4168 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AR</td>
###xml 4192 4195 4168 4171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPA</italic>
###xml 4195 4195 4171 4171 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4195 4206 4171 4182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC3 (XPB)</italic>
###xml 4206 4206 4182 4182 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4206 4209 4182 4185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC</italic>
###xml 4209 4209 4185 4185 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4209 4219 4185 4195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC2(XPD)</italic>
###xml 4219 4219 4195 4195 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4219 4228 4195 4204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDB2(XPE)</italic>
###xml 4228 4228 4204 4204 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4228 4238 4204 4214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC4(XPF)</italic>
###xml 4238 4238 4214 4214 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4238 4248 4214 4224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERCC5(XPG)</italic>
###xml 4248 4248 4224 4224 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4248 4258 4224 4234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POLH(XP-V)</italic>
###xml 4192 4258 4168 4234 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>XPA</italic><break/><italic>ERCC3 (XPB)</italic><break/><italic>XPC</italic><break/><italic>ERCC2(XPD)</italic><break/><italic>DDB2(XPE)</italic><break/><italic>ERCC4(XPF)</italic><break/><italic>ERCC5(XPG)</italic><break/><italic>POLH(XP-V)</italic></td>
###xml 4262 4262 4238 4238 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4258 4266 4234 4242 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Skin<break/>Eyes</td>
###xml 4333 4335 4309 4311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR87">87</xref>
###xml 4336 4338 4312 4314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR88">88</xref>
###xml 4266 4339 4242 4315 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BC and GC have both independently been reported with the syndrome [<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref>]</td>
###xml 4169 4339 4145 4315 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Xeroderma pigmentosum</td><td align="left">AR</td><td align="left"><italic>XPA</italic><break/><italic>ERCC3 (XPB)</italic><break/><italic>XPC</italic><break/><italic>ERCC2(XPD)</italic><break/><italic>DDB2(XPE)</italic><break/><italic>ERCC4(XPF)</italic><break/><italic>ERCC5(XPG)</italic><break/><italic>POLH(XP-V)</italic></td><td align="left">Skin<break/>Eyes</td><td align="left">BC and GC have both independently been reported with the syndrome [<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr>
###xml 4339 4354 4315 4330 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Werner Syndrome</td>
###xml 4354 4356 4330 4332 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AR</td>
###xml 4356 4359 4332 4335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WRN</italic>
###xml 4356 4359 4332 4335 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>WRN</italic></td>
###xml 4377 4377 4353 4353 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4381 4381 4357 4357 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4359 4388 4335 4364 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Connective tissue <break/>Skin<break/>Thyroid</td>
###xml 4443 4445 4419 4421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR89">89</xref>
###xml 4447 4447 4423 4423 <break xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 4550 4553 4526 4529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WRN</italic>
###xml 4637 4640 4613 4616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WRN</italic>
###xml 4655 4659 4631 4635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 4730 4732 4706 4708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR90">90</xref>
###xml 4388 4734 4364 4710 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR89">89</xref>] <break/>There are no reports of BC in association with Werner syndrome. Although, there is evidence supporting <italic>WRN</italic> as a low-penetrance familial BC susceptibility gene, where patients harboring both <italic>WRN</italic> Cys1367Arg or <italic>TP53</italic> MspI variants had an increased BC risk (OR&#160;=&#160;3.39, 95% CI 1.19&#8211;9.71) [<xref ref-type="bibr" rid="CR90">90</xref>] </td>
###xml 4339 4734 4315 4710 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Werner Syndrome</td><td align="left">AR</td><td align="left"><italic>WRN</italic></td><td align="left">Connective tissue <break/>Skin<break/>Thyroid</td><td align="left">GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR89">89</xref>] <break/>There are no reports of BC in association with Werner syndrome. Although, there is evidence supporting <italic>WRN</italic> as a low-penetrance familial BC susceptibility gene, where patients harboring both <italic>WRN</italic> Cys1367Arg or <italic>TP53</italic> MspI variants had an increased BC risk (OR&#160;=&#160;3.39, 95% CI 1.19&#8211;9.71) [<xref ref-type="bibr" rid="CR90">90</xref>] </td></tr>
###xml 899 4734 899 4710 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">BRCA2 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA2</italic></td><td align="left">Breast<break/>Ovary<break/>Larynx<break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 45% (95% confidence interval (CI) 31&#8211;56%) [<xref ref-type="bibr" rid="CR59">59</xref>]<break/>Familial aggregations of both BC and GC have been reported [<xref ref-type="bibr" rid="CR60">60</xref>]<break/>In a study of 173 families, relative risk for GC was 2.6 [<xref ref-type="bibr" rid="CR61">61</xref>]<break/>Among Ashkenazi Jewish GC patients, the frequency of 617delT mutation is five times that of the general Ashkenazi Jewish population frequency [<xref ref-type="bibr" rid="CR62">62</xref>] <break/>Among other cancers, GC occurred in first degree relatives when mutations were located in the ovarian cancer cluster region of exon 11 of <italic>BRCA2</italic> [<xref ref-type="bibr" rid="CR63">63</xref>] </td></tr><tr><td align="left">BRCA1 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA1</italic></td><td align="left">Breast<break/>Ovary <break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 72.8% (95% confidence interval [CI]&#160;=&#160;67.9% to 77.7%) [<xref ref-type="bibr" rid="CR64">64</xref>]<break/>There is a 4 times increased risk for GC [<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left">Peutz-Jeghers Syndrome</td><td align="left">AD</td><td align="left"><italic>STK 11</italic></td><td align="left">Gastrointestinal (GI) tract</td><td align="left">GC is considered an integral tumor of the syndrome with a relative risk of 213 (95% confidence interval 96&#8211;368) [<xref ref-type="bibr" rid="CR65">65</xref>] <break/>BC is considered an integral tumor of the syndrome with a relative risk of 15.2 (95% CI 7.6&#8211;27) [<xref ref-type="bibr" rid="CR65">65</xref>] </td></tr><tr><td align="left">Cowden Syndrome</td><td align="left">AD</td><td align="left"><italic>PTEN</italic></td><td align="left">Breast<break/>Thyroid<break/>Endometrium</td><td align="left">BC is considered an integral tumor of the syndrome with an incidence of 22&#8211;50% [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]<break/>GC in&#160;situ has been reported in a patient with Cowden Syndrome [<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td align="left">Li-Fraumeni Syndrome</td><td align="left">AD</td><td align="left"><italic>TP53</italic><break/><italic>CHK2</italic></td><td align="left">Breast<break/>Adrenal cortex<break/>Connective tissue<break/>Kidney<break/>Nervous system<break/>Pancreas <break/>White blood cells</td><td align="left">BC is frequently found in families with this cancer susceptibility syndrome [<xref ref-type="bibr" rid="CR69">69</xref>]<break/>Chompret expanded the spectrum of cancers to include GC [<xref ref-type="bibr" rid="CR70">70</xref>]<break/>Germline <italic>TP53</italic> mutations have been found in GC families without <italic>CDH1</italic> mutations [<xref ref-type="bibr" rid="CR71">71</xref>&#8211;<xref ref-type="bibr" rid="CR73">73</xref>]<break/>The 1100delC <italic>CHK2</italic> allele confers a 2.2 fold risk of BC to carriers [<xref ref-type="bibr" rid="CR29">29</xref>], however germline mutations in GC kindreds have not been identified [<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left">Familial Adenomatous Polyposis</td><td align="left">AD</td><td align="left"><italic>APC</italic></td><td align="left">Colon and rectum<break/>Duodenum<break/>Thyroid<break/>Pancreas</td><td align="left">Literature review by Shimoyama et&#160;al. totalled 30 reported cases of GC and FAP [<xref ref-type="bibr" rid="CR76">76</xref>]<break/>47% to 49% of primary BCs had promoter hypermethylation at the <italic>APC</italic> locus [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]<break/>23% of LBCs have been shown to have LOH of <italic>APC</italic> [<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left">Lynch Syndrome (Hereditary Nonpolyposis Colon Cancer (HNPCC))</td><td align="left">AD</td><td align="left"><italic>hMSH2</italic><break/><italic>hMLH1</italic><break/><italic>hMSH6</italic><break/><italic>hPMS1</italic><break/><italic>hPMS2</italic></td><td align="left">Colon and rectum<break/>Endometrium<break/>Stomach <break/>Small intestine<break/>Urothelium<break/>Kidney<break/>Ovary<break/>Skin<break/>Pancreas<break/>Brain<break/>White blood cells <break/>Biliary tract</td><td align="left">Gastric cancer accounted for 5% of cancers in families harboring <italic>MLH1</italic> or <italic>MSH2</italic> mutations [<xref ref-type="bibr" rid="CR76">76</xref>]<break/><italic>hMLH1</italic> mutations in large kindred segregated with BCs exhibiting microsatellite instability (MSI) [<xref ref-type="bibr" rid="CR79">79</xref>]<break/>A slight increased incidence of BC was seen in <italic>hMLH1</italic> mutation carriers [<xref ref-type="bibr" rid="CR80">80</xref>]<break/>Germline <italic>hMSH2</italic> mutation carrier with BC exhibited LOH for <italic>hMSH2</italic> in tumors analyzed [<xref ref-type="bibr" rid="CR81">81</xref>]<break/>Analysis of primary invasive BCs demonstrated that 25% of tumours were immunonegative for MSH2 staining [<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left">&#160;Ataxia-telangiectasia (AT)</td><td align="left">AR</td><td align="left"><italic>ATM</italic></td><td align="left">White blood cells</td><td align="left">Mutations causing AT in homozygotes, confer susceptibility to BC in heterozygotes, where women with <italic>ATM</italic> mutations have a &#8764;2-fold risk of BC and &#8764;15% of these women will develop the disease [<xref ref-type="bibr" rid="CR32">32</xref>]<break/>GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR83">83</xref>&#8211;<xref ref-type="bibr" rid="CR85">85</xref>]<break/>There is evidence of excess risks of GC in heterozygotes (RR&#160;=&#160;3.39, 95% CI&#160;=&#160;0.86 to 13.4) [<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td align="left">Xeroderma pigmentosum</td><td align="left">AR</td><td align="left"><italic>XPA</italic><break/><italic>ERCC3 (XPB)</italic><break/><italic>XPC</italic><break/><italic>ERCC2(XPD)</italic><break/><italic>DDB2(XPE)</italic><break/><italic>ERCC4(XPF)</italic><break/><italic>ERCC5(XPG)</italic><break/><italic>POLH(XP-V)</italic></td><td align="left">Skin<break/>Eyes</td><td align="left">BC and GC have both independently been reported with the syndrome [<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td align="left">Werner Syndrome</td><td align="left">AR</td><td align="left"><italic>WRN</italic></td><td align="left">Connective tissue <break/>Skin<break/>Thyroid</td><td align="left">GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR89">89</xref>] <break/>There are no reports of BC in association with Werner syndrome. Although, there is evidence supporting <italic>WRN</italic> as a low-penetrance familial BC susceptibility gene, where patients harboring both <italic>WRN</italic> Cys1367Arg or <italic>TP53</italic> MspI variants had an increased BC risk (OR&#160;=&#160;3.39, 95% CI 1.19&#8211;9.71) [<xref ref-type="bibr" rid="CR90">90</xref>] </td></tr></tbody>
###xml 785 4734 785 4710 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Syndrome</th><th align="left">Mode of inheritance</th><th align="left">Associated gene(s)</th><th align="left">Sites of primary cancer(s)</th><th align="left">Evidence for association with the syndrome </th></tr></thead><tbody><tr><td align="left">BRCA2 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA2</italic></td><td align="left">Breast<break/>Ovary<break/>Larynx<break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 45% (95% confidence interval (CI) 31&#8211;56%) [<xref ref-type="bibr" rid="CR59">59</xref>]<break/>Familial aggregations of both BC and GC have been reported [<xref ref-type="bibr" rid="CR60">60</xref>]<break/>In a study of 173 families, relative risk for GC was 2.6 [<xref ref-type="bibr" rid="CR61">61</xref>]<break/>Among Ashkenazi Jewish GC patients, the frequency of 617delT mutation is five times that of the general Ashkenazi Jewish population frequency [<xref ref-type="bibr" rid="CR62">62</xref>] <break/>Among other cancers, GC occurred in first degree relatives when mutations were located in the ovarian cancer cluster region of exon 11 of <italic>BRCA2</italic> [<xref ref-type="bibr" rid="CR63">63</xref>] </td></tr><tr><td align="left">BRCA1 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA1</italic></td><td align="left">Breast<break/>Ovary <break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 72.8% (95% confidence interval [CI]&#160;=&#160;67.9% to 77.7%) [<xref ref-type="bibr" rid="CR64">64</xref>]<break/>There is a 4 times increased risk for GC [<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left">Peutz-Jeghers Syndrome</td><td align="left">AD</td><td align="left"><italic>STK 11</italic></td><td align="left">Gastrointestinal (GI) tract</td><td align="left">GC is considered an integral tumor of the syndrome with a relative risk of 213 (95% confidence interval 96&#8211;368) [<xref ref-type="bibr" rid="CR65">65</xref>] <break/>BC is considered an integral tumor of the syndrome with a relative risk of 15.2 (95% CI 7.6&#8211;27) [<xref ref-type="bibr" rid="CR65">65</xref>] </td></tr><tr><td align="left">Cowden Syndrome</td><td align="left">AD</td><td align="left"><italic>PTEN</italic></td><td align="left">Breast<break/>Thyroid<break/>Endometrium</td><td align="left">BC is considered an integral tumor of the syndrome with an incidence of 22&#8211;50% [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]<break/>GC in&#160;situ has been reported in a patient with Cowden Syndrome [<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td align="left">Li-Fraumeni Syndrome</td><td align="left">AD</td><td align="left"><italic>TP53</italic><break/><italic>CHK2</italic></td><td align="left">Breast<break/>Adrenal cortex<break/>Connective tissue<break/>Kidney<break/>Nervous system<break/>Pancreas <break/>White blood cells</td><td align="left">BC is frequently found in families with this cancer susceptibility syndrome [<xref ref-type="bibr" rid="CR69">69</xref>]<break/>Chompret expanded the spectrum of cancers to include GC [<xref ref-type="bibr" rid="CR70">70</xref>]<break/>Germline <italic>TP53</italic> mutations have been found in GC families without <italic>CDH1</italic> mutations [<xref ref-type="bibr" rid="CR71">71</xref>&#8211;<xref ref-type="bibr" rid="CR73">73</xref>]<break/>The 1100delC <italic>CHK2</italic> allele confers a 2.2 fold risk of BC to carriers [<xref ref-type="bibr" rid="CR29">29</xref>], however germline mutations in GC kindreds have not been identified [<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left">Familial Adenomatous Polyposis</td><td align="left">AD</td><td align="left"><italic>APC</italic></td><td align="left">Colon and rectum<break/>Duodenum<break/>Thyroid<break/>Pancreas</td><td align="left">Literature review by Shimoyama et&#160;al. totalled 30 reported cases of GC and FAP [<xref ref-type="bibr" rid="CR76">76</xref>]<break/>47% to 49% of primary BCs had promoter hypermethylation at the <italic>APC</italic> locus [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]<break/>23% of LBCs have been shown to have LOH of <italic>APC</italic> [<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left">Lynch Syndrome (Hereditary Nonpolyposis Colon Cancer (HNPCC))</td><td align="left">AD</td><td align="left"><italic>hMSH2</italic><break/><italic>hMLH1</italic><break/><italic>hMSH6</italic><break/><italic>hPMS1</italic><break/><italic>hPMS2</italic></td><td align="left">Colon and rectum<break/>Endometrium<break/>Stomach <break/>Small intestine<break/>Urothelium<break/>Kidney<break/>Ovary<break/>Skin<break/>Pancreas<break/>Brain<break/>White blood cells <break/>Biliary tract</td><td align="left">Gastric cancer accounted for 5% of cancers in families harboring <italic>MLH1</italic> or <italic>MSH2</italic> mutations [<xref ref-type="bibr" rid="CR76">76</xref>]<break/><italic>hMLH1</italic> mutations in large kindred segregated with BCs exhibiting microsatellite instability (MSI) [<xref ref-type="bibr" rid="CR79">79</xref>]<break/>A slight increased incidence of BC was seen in <italic>hMLH1</italic> mutation carriers [<xref ref-type="bibr" rid="CR80">80</xref>]<break/>Germline <italic>hMSH2</italic> mutation carrier with BC exhibited LOH for <italic>hMSH2</italic> in tumors analyzed [<xref ref-type="bibr" rid="CR81">81</xref>]<break/>Analysis of primary invasive BCs demonstrated that 25% of tumours were immunonegative for MSH2 staining [<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left">&#160;Ataxia-telangiectasia (AT)</td><td align="left">AR</td><td align="left"><italic>ATM</italic></td><td align="left">White blood cells</td><td align="left">Mutations causing AT in homozygotes, confer susceptibility to BC in heterozygotes, where women with <italic>ATM</italic> mutations have a &#8764;2-fold risk of BC and &#8764;15% of these women will develop the disease [<xref ref-type="bibr" rid="CR32">32</xref>]<break/>GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR83">83</xref>&#8211;<xref ref-type="bibr" rid="CR85">85</xref>]<break/>There is evidence of excess risks of GC in heterozygotes (RR&#160;=&#160;3.39, 95% CI&#160;=&#160;0.86 to 13.4) [<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td align="left">Xeroderma pigmentosum</td><td align="left">AR</td><td align="left"><italic>XPA</italic><break/><italic>ERCC3 (XPB)</italic><break/><italic>XPC</italic><break/><italic>ERCC2(XPD)</italic><break/><italic>DDB2(XPE)</italic><break/><italic>ERCC4(XPF)</italic><break/><italic>ERCC5(XPG)</italic><break/><italic>POLH(XP-V)</italic></td><td align="left">Skin<break/>Eyes</td><td align="left">BC and GC have both independently been reported with the syndrome [<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td align="left">Werner Syndrome</td><td align="left">AR</td><td align="left"><italic>WRN</italic></td><td align="left">Connective tissue <break/>Skin<break/>Thyroid</td><td align="left">GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR89">89</xref>] <break/>There are no reports of BC in association with Werner syndrome. Although, there is evidence supporting <italic>WRN</italic> as a low-penetrance familial BC susceptibility gene, where patients harboring both <italic>WRN</italic> Cys1367Arg or <italic>TP53</italic> MspI variants had an increased BC risk (OR&#160;=&#160;3.39, 95% CI 1.19&#8211;9.71) [<xref ref-type="bibr" rid="CR90">90</xref>] </td></tr></tbody></table>
###xml 4734 4783 4710 4759 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">AD&#160;=&#160;autosomal dominant, AR&#160;=&#160;autosomal recessive</p>
###xml 4734 4783 4710 4759 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">AD&#160;=&#160;autosomal dominant, AR&#160;=&#160;autosomal recessive</p></table-wrap-foot>
###xml 704 4783 704 4759 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="34">Other syndromes with familial susceptibility to breast and gastric cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Syndrome</th><th align="left">Mode of inheritance</th><th align="left">Associated gene(s)</th><th align="left">Sites of primary cancer(s)</th><th align="left">Evidence for association with the syndrome </th></tr></thead><tbody><tr><td align="left">BRCA2 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA2</italic></td><td align="left">Breast<break/>Ovary<break/>Larynx<break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 45% (95% confidence interval (CI) 31&#8211;56%) [<xref ref-type="bibr" rid="CR59">59</xref>]<break/>Familial aggregations of both BC and GC have been reported [<xref ref-type="bibr" rid="CR60">60</xref>]<break/>In a study of 173 families, relative risk for GC was 2.6 [<xref ref-type="bibr" rid="CR61">61</xref>]<break/>Among Ashkenazi Jewish GC patients, the frequency of 617delT mutation is five times that of the general Ashkenazi Jewish population frequency [<xref ref-type="bibr" rid="CR62">62</xref>] <break/>Among other cancers, GC occurred in first degree relatives when mutations were located in the ovarian cancer cluster region of exon 11 of <italic>BRCA2</italic> [<xref ref-type="bibr" rid="CR63">63</xref>] </td></tr><tr><td align="left">BRCA1 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA1</italic></td><td align="left">Breast<break/>Ovary <break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 72.8% (95% confidence interval [CI]&#160;=&#160;67.9% to 77.7%) [<xref ref-type="bibr" rid="CR64">64</xref>]<break/>There is a 4 times increased risk for GC [<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left">Peutz-Jeghers Syndrome</td><td align="left">AD</td><td align="left"><italic>STK 11</italic></td><td align="left">Gastrointestinal (GI) tract</td><td align="left">GC is considered an integral tumor of the syndrome with a relative risk of 213 (95% confidence interval 96&#8211;368) [<xref ref-type="bibr" rid="CR65">65</xref>] <break/>BC is considered an integral tumor of the syndrome with a relative risk of 15.2 (95% CI 7.6&#8211;27) [<xref ref-type="bibr" rid="CR65">65</xref>] </td></tr><tr><td align="left">Cowden Syndrome</td><td align="left">AD</td><td align="left"><italic>PTEN</italic></td><td align="left">Breast<break/>Thyroid<break/>Endometrium</td><td align="left">BC is considered an integral tumor of the syndrome with an incidence of 22&#8211;50% [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]<break/>GC in&#160;situ has been reported in a patient with Cowden Syndrome [<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td align="left">Li-Fraumeni Syndrome</td><td align="left">AD</td><td align="left"><italic>TP53</italic><break/><italic>CHK2</italic></td><td align="left">Breast<break/>Adrenal cortex<break/>Connective tissue<break/>Kidney<break/>Nervous system<break/>Pancreas <break/>White blood cells</td><td align="left">BC is frequently found in families with this cancer susceptibility syndrome [<xref ref-type="bibr" rid="CR69">69</xref>]<break/>Chompret expanded the spectrum of cancers to include GC [<xref ref-type="bibr" rid="CR70">70</xref>]<break/>Germline <italic>TP53</italic> mutations have been found in GC families without <italic>CDH1</italic> mutations [<xref ref-type="bibr" rid="CR71">71</xref>&#8211;<xref ref-type="bibr" rid="CR73">73</xref>]<break/>The 1100delC <italic>CHK2</italic> allele confers a 2.2 fold risk of BC to carriers [<xref ref-type="bibr" rid="CR29">29</xref>], however germline mutations in GC kindreds have not been identified [<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left">Familial Adenomatous Polyposis</td><td align="left">AD</td><td align="left"><italic>APC</italic></td><td align="left">Colon and rectum<break/>Duodenum<break/>Thyroid<break/>Pancreas</td><td align="left">Literature review by Shimoyama et&#160;al. totalled 30 reported cases of GC and FAP [<xref ref-type="bibr" rid="CR76">76</xref>]<break/>47% to 49% of primary BCs had promoter hypermethylation at the <italic>APC</italic> locus [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]<break/>23% of LBCs have been shown to have LOH of <italic>APC</italic> [<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left">Lynch Syndrome (Hereditary Nonpolyposis Colon Cancer (HNPCC))</td><td align="left">AD</td><td align="left"><italic>hMSH2</italic><break/><italic>hMLH1</italic><break/><italic>hMSH6</italic><break/><italic>hPMS1</italic><break/><italic>hPMS2</italic></td><td align="left">Colon and rectum<break/>Endometrium<break/>Stomach <break/>Small intestine<break/>Urothelium<break/>Kidney<break/>Ovary<break/>Skin<break/>Pancreas<break/>Brain<break/>White blood cells <break/>Biliary tract</td><td align="left">Gastric cancer accounted for 5% of cancers in families harboring <italic>MLH1</italic> or <italic>MSH2</italic> mutations [<xref ref-type="bibr" rid="CR76">76</xref>]<break/><italic>hMLH1</italic> mutations in large kindred segregated with BCs exhibiting microsatellite instability (MSI) [<xref ref-type="bibr" rid="CR79">79</xref>]<break/>A slight increased incidence of BC was seen in <italic>hMLH1</italic> mutation carriers [<xref ref-type="bibr" rid="CR80">80</xref>]<break/>Germline <italic>hMSH2</italic> mutation carrier with BC exhibited LOH for <italic>hMSH2</italic> in tumors analyzed [<xref ref-type="bibr" rid="CR81">81</xref>]<break/>Analysis of primary invasive BCs demonstrated that 25% of tumours were immunonegative for MSH2 staining [<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left">&#160;Ataxia-telangiectasia (AT)</td><td align="left">AR</td><td align="left"><italic>ATM</italic></td><td align="left">White blood cells</td><td align="left">Mutations causing AT in homozygotes, confer susceptibility to BC in heterozygotes, where women with <italic>ATM</italic> mutations have a &#8764;2-fold risk of BC and &#8764;15% of these women will develop the disease [<xref ref-type="bibr" rid="CR32">32</xref>]<break/>GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR83">83</xref>&#8211;<xref ref-type="bibr" rid="CR85">85</xref>]<break/>There is evidence of excess risks of GC in heterozygotes (RR&#160;=&#160;3.39, 95% CI&#160;=&#160;0.86 to 13.4) [<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td align="left">Xeroderma pigmentosum</td><td align="left">AR</td><td align="left"><italic>XPA</italic><break/><italic>ERCC3 (XPB)</italic><break/><italic>XPC</italic><break/><italic>ERCC2(XPD)</italic><break/><italic>DDB2(XPE)</italic><break/><italic>ERCC4(XPF)</italic><break/><italic>ERCC5(XPG)</italic><break/><italic>POLH(XP-V)</italic></td><td align="left">Skin<break/>Eyes</td><td align="left">BC and GC have both independently been reported with the syndrome [<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td align="left">Werner Syndrome</td><td align="left">AR</td><td align="left"><italic>WRN</italic></td><td align="left">Connective tissue <break/>Skin<break/>Thyroid</td><td align="left">GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR89">89</xref>] <break/>There are no reports of BC in association with Werner syndrome. Although, there is evidence supporting <italic>WRN</italic> as a low-penetrance familial BC susceptibility gene, where patients harboring both <italic>WRN</italic> Cys1367Arg or <italic>TP53</italic> MspI variants had an increased BC risk (OR&#160;=&#160;3.39, 95% CI 1.19&#8211;9.71) [<xref ref-type="bibr" rid="CR90">90</xref>] </td></tr></tbody></table><table-wrap-foot><p textid="35">AD&#160;=&#160;autosomal dominant, AR&#160;=&#160;autosomal recessive</p></table-wrap-foot></table-wrap>
###xml 1279 1287 <span type="species:ncbi:9606">patients</span>
###xml 2272 2279 <span type="species:ncbi:9606">patient</span>
###xml 3884 3889 <span type="species:ncbi:9606">women</span>
###xml 3977 3982 <span type="species:ncbi:9606">women</span>
###xml 4613 4621 <span type="species:ncbi:9606">patients</span>
HDGC is one of a number of hereditary cancer syndromes that feature both an increased breast and gastric cancer risk (Table 1). In general, a lack of shared genetic risks for most breast and GI cancers was suggested through a recent study of 13,023 genes in 11 breast and 11 colon cancer cell lines in which the only commonly mutated gene between these two cancer types is p53 [58]. This likely reflects underlying differences in the biology of these diseases, however also highlights the unique nature of germline mutations in the CDH1 gene which are strongly associated with specific histologically defined subtypes of breast and GI cancer, namely LBC and DGC which are both part of the HDGC syndrome. Table 1Other syndromes with familial susceptibility to breast and gastric cancersSyndromeMode of inheritanceAssociated gene(s)Sites of primary cancer(s)Evidence for association with the syndrome BRCA2 Hereditary Breast/Ovarian CancerADBRCA2BreastOvaryLarynxProstateBC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 45% (95% confidence interval (CI) 31-56%) [59]Familial aggregations of both BC and GC have been reported [60]In a study of 173 families, relative risk for GC was 2.6 [61]Among Ashkenazi Jewish GC patients, the frequency of 617delT mutation is five times that of the general Ashkenazi Jewish population frequency [62] Among other cancers, GC occurred in first degree relatives when mutations were located in the ovarian cancer cluster region of exon 11 of BRCA2 [63] BRCA1 Hereditary Breast/Ovarian CancerADBRCA1BreastOvary ProstateBC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 72.8% (95% confidence interval [CI] = 67.9% to 77.7%) [64]There is a 4 times increased risk for GC [64]Peutz-Jeghers SyndromeADSTK 11Gastrointestinal (GI) tractGC is considered an integral tumor of the syndrome with a relative risk of 213 (95% confidence interval 96-368) [65] BC is considered an integral tumor of the syndrome with a relative risk of 15.2 (95% CI 7.6-27) [65] Cowden SyndromeADPTENBreastThyroidEndometriumBC is considered an integral tumor of the syndrome with an incidence of 22-50% [66, 67]GC in situ has been reported in a patient with Cowden Syndrome [68]Li-Fraumeni SyndromeADTP53CHK2BreastAdrenal cortexConnective tissueKidneyNervous systemPancreas White blood cellsBC is frequently found in families with this cancer susceptibility syndrome [69]Chompret expanded the spectrum of cancers to include GC [70]Germline TP53 mutations have been found in GC families without CDH1 mutations [71-73]The 1100delC CHK2 allele confers a 2.2 fold risk of BC to carriers [29], however germline mutations in GC kindreds have not been identified [74]Familial Adenomatous PolyposisADAPCColon and rectumDuodenumThyroidPancreasLiterature review by Shimoyama et al. totalled 30 reported cases of GC and FAP [76]47% to 49% of primary BCs had promoter hypermethylation at the APC locus [77, 78]23% of LBCs have been shown to have LOH of APC [43]Lynch Syndrome (Hereditary Nonpolyposis Colon Cancer (HNPCC))ADhMSH2hMLH1hMSH6hPMS1hPMS2Colon and rectumEndometriumStomach Small intestineUrotheliumKidneyOvarySkinPancreasBrainWhite blood cells Biliary tractGastric cancer accounted for 5% of cancers in families harboring MLH1 or MSH2 mutations [76]hMLH1 mutations in large kindred segregated with BCs exhibiting microsatellite instability (MSI) [79]A slight increased incidence of BC was seen in hMLH1 mutation carriers [80]Germline hMSH2 mutation carrier with BC exhibited LOH for hMSH2 in tumors analyzed [81]Analysis of primary invasive BCs demonstrated that 25% of tumours were immunonegative for MSH2 staining [82] Ataxia-telangiectasia (AT)ARATMWhite blood cellsMutations causing AT in homozygotes, confer susceptibility to BC in heterozygotes, where women with ATM mutations have a approximately2-fold risk of BC and approximately15% of these women will develop the disease [32]GC has been reported in association with the syndrome [83-85]There is evidence of excess risks of GC in heterozygotes (RR = 3.39, 95% CI = 0.86 to 13.4) [86]Xeroderma pigmentosumARXPAERCC3 (XPB)XPCERCC2(XPD)DDB2(XPE)ERCC4(XPF)ERCC5(XPG)POLH(XP-V)SkinEyesBC and GC have both independently been reported with the syndrome [87,88]Werner SyndromeARWRNConnective tissue SkinThyroidGC has been reported in association with the syndrome [89] There are no reports of BC in association with Werner syndrome. Although, there is evidence supporting WRN as a low-penetrance familial BC susceptibility gene, where patients harboring both WRN Cys1367Arg or TP53 MspI variants had an increased BC risk (OR = 3.39, 95% CI 1.19-9.71) [90] AD = autosomal dominant, AR = autosomal recessive
###end p 33
###begin p 34
Other syndromes with familial susceptibility to breast and gastric cancers
###end p 34
###begin p 35
AD = autosomal dominant, AR = autosomal recessive
###end p 35
###begin p 36
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 678 682 678 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 737 741 737 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
With the recent demonstration of a CDH1 mutation in a family ascertained through an index case of LBC and in view of the additional new mutation in a predominantly breast cancer family that we have described here, the evidence for establishing LBC as part of the HDGC syndrome is strong. There now is a need for establishing the prevalence of CDH1 mutations in LBC families to avoid the ascertainment bias generated from only looking at cases from families identified because of their family history of GC. It is not currently known what the risk of GC is in these families which present predominantly as having a susceptibility to breast cancer and therefore identification of CDH1 as a true susceptibility gene for LBC could result in CDH1 screening and effective risk reduction strategies for selected breast cancer families and further studies examining their risk for gastric and other cancers.
###end p 36
###begin p 37
###xml 124 128 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
Most hereditary cancer syndromes are associated with cancer risk involving multiple organs. Here we have discussed germline CDH1 mutations and the risks with regard to DGC and LBC, however as the recognised spectrum of related cancers broadens, more affected families will be identified and successfully managed with regard to avoidance of specific cancer risks. Longer life expectancy in individuals with penetrant mutations could potentially lead to the development of different, later onset disease as yet to be identified in these kindreds. This represents a particular challenge in hereditary cancer practice as the clinical community tends to be segregated into organ specific specialties where as the cancer risks and the risk reduction strategies for germline mutation carriers require a variety of expertise. The medical needs of the HDGC families are therefore best served through an engaged multidisciplinary team.
###end p 37
###begin title 38
Acknowledgements
###end title 38
###begin p 39
This work was supported in part by the National Cancer Institute of Canada (NCIC) and the British Columbia/Yukon Territory chapter of the Canadian Breast Cancer Foundation. DGH is a Michael Smith Foundation for Health Research Senior Scholar.
###end p 39
###begin p 40
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 40
###begin title 41
References
###end title 41
###begin article-title 42
Epidemiology of gastric cancer
###end article-title 42
###begin article-title 43
Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type
###end article-title 43
###begin article-title 44
E-cadherin germline mutations in familial gastric cancer
###end article-title 44
###begin article-title 45
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer
###end article-title 45
###begin article-title 46
###xml 79 86 <span type="species:ncbi:9606">patient</span>
Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation
###end article-title 46
###begin article-title 47
Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management
###end article-title 47
###begin article-title 48
Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred
###end article-title 48
###begin article-title 49
Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria
###end article-title 49
###begin article-title 50
Germline E-Cadherin mutations in familial lobular breast cancer
###end article-title 50
###begin article-title 51
The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice
###end article-title 51
###begin article-title 52
###xml 17 22 <span type="species:ncbi:9606">human</span>
Mutations of the human E-cadherin (CDH1) gene
###end article-title 52
###begin article-title 53
Cadherin-catenin complex: protein interactions and their implications for cadherin function
###end article-title 53
###begin article-title 54
Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion
###end article-title 54
###begin article-title 55
Role of p120-catenin in cadherin trafficking
###end article-title 55
###begin article-title 56
Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role
###end article-title 56
###begin article-title 57
###xml 50 55 <span type="species:ncbi:9606">human</span>
E-cadherin-catenin cell-cell adhesion complex and human cancer
###end article-title 57
###begin article-title 58
Signaling through beta-catenin and Lef/Tcf
###end article-title 58
###begin article-title 59
E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation
###end article-title 59
###begin article-title 60
Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene
###end article-title 60
###begin article-title 61
###xml 114 121 <span type="species:ncbi:9606">patient</span>
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening
###end article-title 61
###begin article-title 62
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ
###end article-title 62
###begin article-title 63
E-cadherin gene mutations provide clues to diffuse type gastric carcinomas
###end article-title 63
###begin article-title 64
Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas
###end article-title 64
###begin article-title 65
E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas
###end article-title 65
###begin article-title 66
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer
###end article-title 66
###begin article-title 67
Recognition and management of hereditary breast cancer syndromes
###end article-title 67
###begin article-title 68
###xml 55 62 <span type="species:ncbi:9606">patient</span>
New insights into breast cancer genetics and impact on patient management
###end article-title 68
###begin article-title 69
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies
###end article-title 69
###begin article-title 70
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles
###end article-title 70
###begin article-title 71
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
###end article-title 71
###begin article-title 72
ATM and breast cancer susceptibility
###end article-title 72
###begin article-title 73
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
###end article-title 73
###begin article-title 74
Lobular breast cancer: excess familiality observed in the Utah Population Database
###end article-title 74
###begin article-title 75
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2
###end article-title 75
###begin article-title 76
Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas
###end article-title 76
###begin article-title 77
###xml 45 55 <span type="species:ncbi:111938">gatekeeper</span>
The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression
###end article-title 77
###begin article-title 78
###xml 52 57 <span type="species:ncbi:9606">human</span>
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain
###end article-title 78
###begin article-title 79
###xml 59 64 <span type="species:ncbi:9606">human</span>
E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers
###end article-title 79
###begin article-title 80
Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast
###end article-title 80
###begin article-title 81
E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma
###end article-title 81
###begin article-title 82
Novel germline CDH1 mutations in hereditary diffuse gastric cancer families
###end article-title 82
###begin article-title 83
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability
###end article-title 83
###begin article-title 84
Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene
###end article-title 84
###begin article-title 85
Low frequency of E-cadherin alterations in familial breast cancer
###end article-title 85
###begin article-title 86
CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk
###end article-title 86
###begin article-title 87
Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families
###end article-title 87
###begin article-title 88
###xml 69 77 <span type="species:ncbi:9606">patients</span>
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
###end article-title 88
###begin article-title 89
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
###end article-title 89
###begin article-title 90
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group
###end article-title 90
###begin article-title 91
###xml 70 75 <span type="species:ncbi:9606">women</span>
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series
###end article-title 91
###begin article-title 92
###xml 20 21 20 21 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
[18F]Fluoro-2-deoxy-d-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier
###end article-title 92
###begin article-title 93
Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy?
###end article-title 93
###begin article-title 94
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations
###end article-title 94
###begin article-title 95
CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer
###end article-title 95
###begin article-title 96
Gastric cancer: new genetic developments
###end article-title 96
###begin article-title 97
###xml 34 39 <span type="species:ncbi:9606">human</span>
The consensus coding sequences of human breast and colorectal cancers
###end article-title 97
###begin article-title 98
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies
###end article-title 98
###begin article-title 99
BRCA2 gene mutations in families with aggregations of breast and stomach cancers
###end article-title 99
###begin article-title 100
###xml 61 69 <span type="species:ncbi:9606">patients</span>
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel
###end article-title 100
###begin article-title 101
###xml 94 99 <span type="species:ncbi:9606">women</span>
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
###end article-title 101
###begin article-title 102
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program
###end article-title 102
###begin article-title 103
Very high risk of cancer in familial Peutz-Jeghers syndrome
###end article-title 103
###begin article-title 104
###xml 56 64 <span type="species:ncbi:9606">patients</span>
The Cowden syndrome: a clinical and genetic study in 21 patients
###end article-title 104
###begin article-title 105
Cowden's disease: a cutaneous marker of breast cancer
###end article-title 105
###begin article-title 106
Parathyroid adenoma and gastric carcinoma as manifestations of Cowden's disease
###end article-title 106
###begin article-title 107
Relative frequency and morphology of cancers in carriers of germline TP53 mutations
###end article-title 107
###begin article-title 108
Sensitivity and predictive value of criteria for p53 germline mutation screening
###end article-title 108
###begin article-title 109
###xml 151 159 <span type="species:ncbi:9606">patients</span>
Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1:contribute to genetic predisposition in German gastric cancer patients
###end article-title 109
###begin article-title 110
A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome
###end article-title 110
###begin article-title 111
###xml 144 152 <span type="species:ncbi:9606">patients</span>
E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients
###end article-title 111
###begin article-title 112
Absence of germline CHK2 mutations in familial gastric cancer
###end article-title 112
###begin article-title 113
###xml 69 76 <span type="species:ncbi:9606">patient</span>
Early gastric cancer development in a familial adenomatous polyposis patient
###end article-title 113
###begin article-title 114
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients
###end article-title 114
###begin article-title 115
Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis
###end article-title 115
###begin article-title 116
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome
###end article-title 116
###begin article-title 117
Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds
###end article-title 117
###begin article-title 118
Breast cancer in an MSH2 gene mutation carrier
###end article-title 118
###begin article-title 119
Loss of hMSH2 expression in primary breast cancer with p53 alterations
###end article-title 119
###begin article-title 120
Ataxia-telangiectasia with gastric adenocarcinoma
###end article-title 120
###begin article-title 121
###xml 32 35 <span type="species:ncbi:9606">boy</span>
Stomach cancer of a 14-year-old boy with ataxia-telangiectasia
###end article-title 121
###begin article-title 122
Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia
###end article-title 122
###begin article-title 123
Cancer risks and mortality in heterozygous ATM mutation carriers
###end article-title 123
###begin article-title 124
Xeroderma pigmentosum with recurrent infiltrating ductal carcinoma of breast
###end article-title 124
###begin article-title 125
###xml 28 35 <span type="species:ncbi:9606">patient</span>
Gastric adenocarcinoma in a patient with xeroderma pigmentosum
###end article-title 125
###begin article-title 126
Werner's syndrome combined with quintuplicate malignant tumors: a case report and review of literature data
###end article-title 126
###begin article-title 127
Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer
###end article-title 127
###begin title 128
Abbreviations
###end title 128
###begin p 129
diffuse gastric cancer
###end p 129
###begin p 130
gastric cancer
###end p 130
###begin p 131
hereditary diffuse gastric cancer
###end p 131
###begin p 132
lobular breast cancer
###end p 132

